


# ACT-Accelerator & COVAX Priorities

WHO Member State Update

---


3 FEBRUARY 2021

ACT now, ACT together to accelerate the end of the COVID-19 crisis




# Today: an evolving pandemic with an evolving virus


102 million cases & 2 million deaths



Variants of Concern in at least 100 countries



**Under investment** in global solutions & increasing bilateral action



**The ACT-Accelerator is evolving in a rapidly changing world....**

**...the new strategy for 2021 reflects these changes**

# Building on ACT-A's vital & unique value-add in 2020: 3 lines of defense against COVID-19 are now in rollout, everywhere



**COVAX Vaccines Facility** will transform collaboration across 190 economies with >2 B doses



**New Rapid Tests (RDTs)** transform capacity to detect infection globally *(with >375m low-cost units for LMICs)*



**1<sup>st</sup> & only proven therapy** (Dexa) transformed ability to save lives



**Fair & equitable allocation mechanism**



**Systems support for rollout**




## 4 Strategic Priorities for 2021



Rapidly scale-up **delivery of >2 B doses of vaccine** through COVAX



Bolster R&D, eval & regulatory pathways, to **optimize products & address variants**



Ensuring 3 robust lines of defense against the virus & variants, everywhere



Stimulate **rapid & effective uptake of tests, therapeutics & PPE**



Ensure **robust pipeline** of essential tests, therapeutics & PPE in LMICs

# ACT-A funding gap by Pillar & Strategic Priority, 2021

Last update: 29 Jan 2021

by Pillar  
USD\$ billions


	Q1/Q2 2021	Q3/Q4 2021	Total 2021
Diagnostics	1.9	7.0	8.9
Therapeutics	1.4	1.8	3.2
Vaccines	7.8	<0.1	7.8
Health Systems Connector	3.2	4.3	7.4
<b>Total</b>	<b>14.2</b>	<b>13.1</b>	<b>27.2</b>



# State of Vaccines: geographies & products (at 4 February 2021<sup>1</sup>)

## Total COVID-19 vaccine doses/100 people


NOTE: single doses, not the total number of people vaccinated



Source: Official data collated by Our World in Data – Last updated 4 February, 09:30 (London time)

## Number of countries using specific vaccine(s)

NOTE: 47 countries are using 1 vaccine; 24 countries using  $\geq 2$  vaccines



<sup>1</sup> NOTE: New activities from 29 January 2021 not yet fully reflected

# WHO Emergency Use Listing (EUL) – indicative review timelines

**December:** Pfizer/BioNTech (30 Dec)

**February:** AZ/Serum Institute of India  
AZ/SK Bio, Korea

**Feb/March:** Sinopharm  
Sinovac

**In discussion:** Gamaleya  
Moderna  
J&J  
Novavax

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process


Manufacturer	Name of Vaccine	EMA, CE, FDA	Platform	WHO EUL	Pre-submission meeting WHO	Device accepted for review	Status of assessment	Anticipated decision date
Pfizer/BioNTech	BNT162b2 (Comirnaty)	EMA, CE, FDA	mRNA	✓	✓	✓	Final review	30 Dec 2020
AZ/Serum Institute of India	CovidShield (COVISHIELD)	EMA, CE, FDA	Adenoviral vector	✓	✓	✓	Final review	21 Feb 2021
AZ/SK Bio	Novavax NVX-CoV2373	EMA, CE, FDA	Protein subunit	✓	✓	✓	Final review	21 Feb 2021
Sinopharm	BBIBP-CorV	EMA, CE, FDA	Inactivated	✓	✓	✓	Final review	21 Feb 2021
Sinovac	CoronaVac	EMA, CE, FDA	Inactivated	✓	✓	✓	Final review	21 Feb 2021
Gamaleya	Sputnik V	EMA, CE, FDA	Adenoviral vector	✓	✓	✓	Final review	21 Feb 2021
Moderna	mRNA-1273	EMA, CE, FDA	mRNA	✓	✓	✓	Final review	21 Feb 2021
J&J	Ad26.COV2.S	EMA, CE, FDA	Adenoviral vector	✓	✓	✓	Final review	21 Feb 2021
Novavax	Novavax NVX-CoV2373	EMA, CE, FDA	Protein subunit	✓	✓	✓	Final review	21 Feb 2021



# COVAX 'Indicative Allocations': from Region to Participant-specific, 29-30 Jan 2021

## Regional & Product views

## Participant view



**THE COVAX FACILITY: INTERIM DISTRIBUTION FORECAST** – latest as of 3 February 2021

**INTRODUCTION**

In line with initial guidance delivered on 22 January, and building on the publication of the 2021 COVAX global and regional supply forecasts, the COVAX Facility is pleased to share the following forecast for the Pfizer-BioNTech vaccine and the AstraZeneca/Oxford vaccine to Facility participants.

This document contains information on indicative distribution of 240 million doses of the Pfizer-BioNTech vaccine, licensed to Serum Institute of India (SII) – hereinafter "AZ/SII" and 96 million doses of the AstraZeneca/Oxford vaccine, under the advance purchase agreement between AstraZeneca – hereinafter "AZ", for Q1 & Q2 2021.

It also contains an overview of exceptional first round allocation of 1.2 million doses of the AstraZeneca/Oxford vaccine to Facility participants in the first half of 2021.

It is important to note additional doses of both these products will be available in the second half of 2021.

**ASTRAZENECA/OXFORD VACCINE: INDICATIVE Q2 2021**

What is an "indicative distribution"?

This indicative distribution is intended to provide interim guidance to Facility participants to enable preparations for the final allocation of the number of doses in the first rounds of vaccine distribution. It is therefore non-binding and may be subject to change. Nevertheless, COVAX partners believe the publication of this information, shared with all economies participating in the COVAX Facility, marks an important step in providing governments and public health leaders with the information they need to put in place arrangements for the provision of early doses and a successful national roll out of vaccines.

Overview of the Process

It is important to note that WHO EUL has not yet been granted for the AstraZeneca/Oxford vaccine. Pending these final decisions, and based on the information provided by AstraZeneca, the COVAX Facility has provided an indicative distribution for each Facility participant.

<sup>1</sup> Three WHO Emergency Use Listing (EUL) evaluations are currently underway in relation to the AstraZeneca/Oxford vaccine, SII BioScience, and Serum Institute of India.

**COVAX Interim Distribution Forecast**  
As of 3 February 2021

**OVERVIEW BY FACILITY PARTICIPANT**

Total doses cover, on average, 3.3% of the total population of the 145 participants receiving doses from at least one manufacturer in the list detailed below. This is in line with the Facility target to reach at least 3% population coverage in all countries in the first half of the year, enough to protect the most vulnerable groups such as health care workers.

Participants that do not appear in the list below have either exercised their rights to opt-out, have not submitted vaccine requests, or have not yet been allocated doses.

Notes of clarification

- For AZ/SII and AZ indicative distribution, delivery is estimated to begin as of late February, subject to WHO EUL, manufacturing supply capacity and completion of pre-requisites, as outlined in the related caveats section, above.
- For AZ/SII, indicative distribution doses specify contracted number of doses for Q1 + Q2 (first half – H1) supply, with 35-40% available in Q1 and 60-65% available in Q2.
- For AZ, range reflects H1 supply, with 15% available in Q1 and 56% available in Q2. Further supply is planned for the second half of the year.
- For Pfizer-BioNTech, doses are those anticipated for Q1 supply, pending successful satisfaction of caveats listed in the relevant section above.

WHO Region	Participant	SFP/AMC	# doses – AZ/SII (indicative distribution)	# doses – AZ/SK Bio (indicative distribution)	# doses – Pfizer-BioNTech (exceptional allocation)
EMRO	Afghanistan	AMC	3,024,000	-	-
EURO	Albania	SFP	-	141,600	-
AFRO	Algeria	AMC	-	2,200,800	-
EURO	Andorra	SFP	-	26,400	-
AFRO	Angola	AMC	2,544,000	-	-
PAHO	Antigua and Barbuda	SFP	-	40,800	-
PAHO	Argentina	SFP	-	2,275,200	-
EURO	Armenia	SFP	-	146,400	-
EURO	Azerbaijan	SFP	-	506,400	-

From 30 Jan, COVAX started sharing Participant-specific 'indicative allocations'

- all Participants informed of 1<sup>st</sup> ½ 2021 projections for AZ/SK Bio & SII/AZ
- all projections subject to EUL (mid-Feb) and volumes
- included outcome of small-scale Pfizer rollout activity (300,000 doses in Feb)

Regional view: <https://www.gavi.org/sites/default/files/covid/covax/COVAX%20Supply%20Forecast.pdf>

Participant view: <https://www.gavi.org/sites/default/files/covid/covax/COVAX-Interim-Distribution-Forecast.pdf>


## Small-scale 1st wave activity with Pfizer vaccine

(i.e. 300,000 doses in February 2021)

72 Participants Expressed Interest

48 had not started vaccination, met readiness criteria<sup>1</sup> and opt-in price

Grouped by **WHO Region & AMC/SFP status** to ensure all represented <sup>2</sup>



Each group ranked by **risk of health worker exposure** (high 28 day mortality = high exposure)

Participants **selected from each group to 18 maximum** for limited Pfizer quantities

WHO, GAVI & UNICEF seeking donations of Pfizer vaccine to expand rollout  
Planning to initiate ASAP for 2<sup>nd</sup> quarter 14 million doses of Pfizer vaccine

Note: The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

## Major developments – **vaccines**

- **Gamaleya** (viral vector; 2 dose): 91.3% efficacy<sup>1</sup>
- **Novavax** (protein subunit; 2 dose):
  - UK interim Phase 3: 89% efficacy<sup>2</sup>
  - South Africa Phase 2b: 60% efficacy (w/o HIV; 90% cases variant)<sup>2</sup>
- **J&J** (viral vector; 1 dose):
  - US Phase 3 interim: 72% efficacy
  - Latin America: 66%
  - South Africa: 57% (moderate & severe disease)<sup>3</sup>
- **AZ** (non-SII): 40-60% volume reductions

1. Source: Lancet [https://doi.org/10.1016/S0140-6736\(21\)00234-8](https://doi.org/10.1016/S0140-6736(21)00234-8)

2. Source: <https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3>

3. Source: <https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial>




# Initiating COVAX vaccination in February:

Regulatory approvals

New deals

Donations



Countries are ready to vaccinate

- Vaccine Request Forms from 88 of 92 AMC countries
- 124 readiness assessments (incl 77/92 AMC countries)
- regulatory pathways in place
- *indemnification language & no-fault compensation* for all 92 AMCs



# Finalizing ACT-A's Prioritized Strategy & Budget 2021

